Evidence map›Paper›PMID 35721607›Full record

ArticleKidney3602022

Longitudinal Associations between Low Serum Bicarbonate and Linear Growth in Children with CKD.

Denver D Brown, Megan Carroll, Derek K Ng, Rebecca V Levy, Larry A Greenbaum, Frederick J Kaskel, Susan L Furth, Bradley A Warady, Michal L Melamed, Andrew Dauber

Registry-linked trialOpen access · diamondAbstract read
In one paragraph

Article in Kidney360, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT00327860 (Chronic Kidney Disease in Children Prospective Cohort Study), which is not on this map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
2.2field-weighted citation impact, top 13% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT00327860 recruitingnot on this map

Chronic Kidney Disease in Children Prospective Cohort Study (CKiD)

TypeobservationalSponsorJohns Hopkins Bloomberg School of Public HealthRan2003 to 2028Enrolled1,300ConditionsChronic Kidney Disease
3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 15 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Hyperkalemia in pediatric chronic kidney disease.Pediatric nephrology (Berlin, Germany) · 2023
    Article
  6. Article
  7. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

10 authors at 8 institutions in 1 country.

Denver D BrownDivision of Nephrology, Children's National Hospital, Washington, DC.ORCID 0000-0003-3381-0336
Megan CarrollJohns Hopkins Bloomberg School of Public Health, Baltimore, Maryland.ORCID 0000-0001-5355-1357
Derek K NgJohns Hopkins Bloomberg School of Public Health, Baltimore, Maryland.ORCID 0000-0001-5878-5101
Rebecca V LevyDivision of Pediatric Nephrology, University of Rochester Medical Center, Rochester, New York.ORCID 0000-0002-6352-996X
Larry A GreenbaumDivision of Pediatric Nephrology, Emory University School of Medicine and Children's Healthcare of Atlanta, Atlanta, Georgia.ORCID 0000-0002-2490-021X
Frederick J KaskelDivision of Pediatric Nephrology, The Children's Hospital at Montefiore, Bronx, New York.
Susan L FurthDivision of Pediatric Nephrology, The Children's Hospital of Philadelphia, Philadelphia, Pennsylvania.
Bradley A WaradyDivision of Pediatric Nephrology, Children's Mercy Hospital, Kansas City, Missouri.
Michal L MelamedDepartment of Medicine, Albert Einstein College of Medicine, Bronx, New York.
Andrew DauberDivision of Endocrinology, Children's National Hospital, Washington, DC.ORCID 0000-0003-4890-0262
Children's National · USJohns Hopkins University · USAlbert Einstein College of Medicine · USChildren's Hospital at Montefiore · USChildren's Hospital of Philadelphia · USChildren's Mercy Hospital · USEmory University · USUniversity of Rochester Medical Center · US

Funding

Chronic Kidney Disease in Children Study (C-Kid)U01DK066174 · NIDDK · JOHNS HOPKINS UNIVERSITY · PI SUSAN L. FURTH · 2003 to 2026
$25.1M
CKiD Cardiovascular Testing Travel SupplementU01DK066143 · NIDDK · CHILDREN'S MERCY HOSP (KANSAS CITY, MO) · PI Bradley Alan Warady · 2003 to 2026
$24.2M
The Kidney Disease in Children Data Management and Analysis Center (KIDMAC)U24DK066116 · NIDDK · JOHNS HOPKINS UNIVERSITY · PI Derek K Ng · 2018 to 2026
$12.6M
Child Health Research Career Development Award (CHRCDA) Program at Children's NationalK12HD001399 · NICHD · CHILDREN'S RESEARCH INSTITUTE · PI NATHAN KUPPERMANN · 2001 to 2026
$9.1M
DEVELOPMENTAL RENAL AND ELECTROLYTE PHYSIOLOGYT32DK007110 · NIDDK · YESHIVA UNIVERSITY · PI KASKEL, FREDERICK JEFFREY, MELAMED, MICHAL L · 1986 to 2021
$5.6M
Central Biochemistry Laboratory of the CKID ConsortiumU24DK082194 · NIDDK · UNIVERSITY OF ROCHESTER · PI SCHWARTZ, GEORGE J · 2018 to 2022
$1.7M
NICHD NIH HHS K12 HD001399NIDDK NIH HHS T32 DK007110NIDDK NIH HHS U01 DK066143NIDDK NIH HHS U01 DK066174NIDDK NIH HHS U24 DK066116NIDDK NIH HHS U24 DK082194
6 · The paper itself

Abstract

Background: Poor linear growth is a consequence of chronic kidney disease (CKD) that has been linked to adverse outcomes. Metabolic acidosis (MA) has been identified as a risk factor for growth failure. We investigated the longitudinal relationship between MA and linear growth in children with CKD and examined whether treatment of MA modified linear growth. Methods: To describe longitudinal associations between MA and linear growth, we used serum bicarbonate levels, height measurements, and standard deviation (z scores) of children enrolled in the prospective cohort study Chronic Kidney Disease in Children. Analyses were adjusted for covariates recognized as correlating with poor growth, including demographic characteristics, glomerular filtration rate (GFR), proteinuria, calcium, phosphate, parathyroid hormone, and CKD duration. CKD diagnoses were analyzed by disease categories, nonglomerular or glomerular. Results: The study population included 1082 children with CKD: 808 with nonglomerular etiologies and 274 with glomerular etiologies. Baseline serum bicarbonate levels ≤22 mEq/L were associated with worse height z scores in all children. Longitudinally, serum bicarbonate levels ≤18 and 19-22 mEq/L were associated with worse height z scores in children with nonglomerular CKD causes, with adjusted mean values of -0.39 (95% CI, -0.58 to -0.2) and -0.17 (95% CI, -0.28 to -0.05), respectively. Children with nonglomerular disease and more severe GFR impairment had a higher risk for worse height z score. A significant association was not found in children with glomerular diseases. We also investigated the potential effect of treatment of MA on height in children with a history of alkali therapy use, finding that only persistent users had a significant positive association between their height z score and higher serum bicarbonate levels. Conclusions: We observed a longitudinal association between MA and lower height z score. Additionally, persistent alkali therapy use was associated with better height z scores. Future clinical trials of alkali therapy need to evaluate this relationship prospectively.

Indexed as

AcidosisRenal Insufficiency, ChronicAlkaliesBicarbonatesChildDisease ProgressionHumansProspective StudiesAlkaliesBicarbonateschildchronic kidney diseasegrowthserum bicarbonate

Identifiers

PMID35721607
PMCPMC9136912
OpenAlexW4210874578

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.